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doi:10.1016/j.gmbhs.2012.04.009Abstract The purpose of this study was to assess the apoptotic -related gene expression of
single-agent oxaliplatin in vitro. Growth inhibition studies were performed using the human
cerebral cavernous malformation-1 colorectal adenocarcinoma cell line and mucosa-
associated lymphoid tissue-nt-1 lymphoma cell line. At 50% inhibitory concentrations, oxalipla-
tin displayed suppressive effects toward Bcl-2 and the surviving expression in human cancer
cell lines, whereas the expression of Fas/FasL was completely abolished in peripheral blood
cells. Our data showed that oxaliplatin exerts potent antiapoptotic effects in human normal
peripheral blood mononuclear cells at the suprapharmacologic concentration, warranting
further investigations in the role of autoimmune adverse events while being used in numerous
cycles for the treatment of malignancies.
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Cis-[(1R,2R)-1,2-cyclohexanediamine-N,N’] [oxalato(2-)-O,O’]
platinumeoxaliplatin (OXA), a third generation antineoplasm
platinumderivative,belongs tothesamefamilyascisplatinand
carboplatin. It is typically administered in combination
with fluorouracil and folinic acid in a chemotherapy regimen
known as FOLFOX for the treatment of colorectal cancer,1 torker Society. Published by Elsevier Taiwan LLC. All rights reserved.
42 G.-C. Huang, H.-S. Liuwhich cisplatin and carboplatin have essentially no activity. As
issues of toxicity, stability, safety, and primary resistancewere
more auspicious for OXA than for the first- and second-
generation platinum compounds, the potential synergism
between OXA and various antimetabolites in the treatment of
other malignancies such as ovarian, mammary, gastric,
pancreatic, leukemic, and mucosa-associated lymphoid tissue
(MALT) lymphoma, is an area of expanding interest.
It is generally recognized that OXA results in DNA-
strand breaks by formation of platinum-DNA (Pt-DNA)
adducts and is responsible for its ability to interfere with
the growth of cancer cells.2 Apoptosis triggered by
a detector-activated damage-responsive signal trans-
duction pathway appears to play an integral role in the
reaction. However, several lines of evidence suggest that
OXA may affect tumor growth by additional mechanisms.
First, a variety of in vitro culture systems has identified
quantitatively lower levels of OXA-DNA adducts compared
with the first generation cisplatin, indicating OXA forms
fewer DNA lesions than does cisplatin to achieve cell
growth inhibition.
Second, it has been shown that the vast majority of the
OXA in the cell never associated with the DNA.3 Consis-
tently, it has also been observed initially that the rate of
protein binding for OXA in an ovarian carcinoma cell line
was also high, implying that cellular proteins might be the
targets as well. Finally, despite the fact that OXA has been
proven as a safe, well-tolerated and effective therapy for
colorectal cancer, the rare but real hematologic toxicity,
ranging from neutropenia to hemolytic anemia, thrombo-
cytopenia, and immune pancytopenia, has been described
as treatment-related grade 3/4 adverse events. Such clin-
ically autoimmune-relevant symptoms, especially in those
patients who received multiple courses of OXA, are
considerable scientific interest and may probably confer
parts of the drug actions.
Since the mechanisms underlying the action of OXA have
not been well defined, this study tries to elucidate the
mechanisms of chemotherapy by detecting apoptosis of two
human tumor cell lines and peripheral blood mononuclear
cells (PBMCs). We report here that the effects on PBMCs
that may accompany the broad spectrum as well as review
the adverse events of this drug.Materials and methods
Growth inhibition studies were performed using the human
cerebral cavernous malformation-1 (CCM-1) colorectal
adenocarcinoma cell line and MALT-nt-1 lymphoma cell
line. In particular, short incubation times have been chosen
to understand the acute drug concentration and the high
dose response in the cells. The expression level of
apoptotic and anti-apoptotic genes were analyzed among
CCM-1, MALT-nt-1, and peripheral blood mononuclear cells
in the condition of the 50% inhibitory concentrations (IC50
values) of CCM-1 in single-drug experiments with a 16-hour
exposure period to oxaliplatin.
Results
The IC50 value of single agent oxaliplatin for CCM-1 was
178 mM. At the IC50, oxaliplatin displayed suppressive
effects toward Bcl-2 and surviving expression in human
cancer cell lines, whereas the expression of Fas/FasL was
completely abolished in peripheral blood cells.
Discussion and conclusion
Our data showed that oxaliplatin exerts potent anti-
apoptotic effects in human normal peripheral blood
mononuclear cells at the suprapharmacologic concentra-
tion, warranting further investigations in the role of auto-
immune side effects while being used in numerous cycles
for the treatment of malignancies.
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